We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-0.58%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$305M
AUM Growth
+$11.7M
Cap. Flow
+$37.1M
Cap. Flow %
12.17%
Top 10 Hldgs %
82.2%
Holding
23
New
6
Increased
3
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$21.6M
2
OPTN
OptiNose
OPTN
+$10.1M
3
OMER icon
Omeros
OMER
+$7.94M
4
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$4.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$4.47M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$3.21M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$2.35M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$2.24M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.72M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$790K

Sector Composition

Rank Sector Weight
1 Healthcare 91.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$21.4B
$36.4M 11.94%
1,800,587
– –
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$33.3M 10.93%
511,244
-54,511
-10% -$3.21M
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$32M 10.48%
851,200
– –
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$25.7M 8.41%
1,231,543
– –
ABUS icon
5
Arbutus Biopharma
ABUS
$857M
$25.3M 8.29%
2,676,825
+25,000
+0.9% +$248K
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$22.4M 7.35%
2,023,369
– –
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$6.81B
$20.3M 6.66%
696,903
-25,000
-3% -$790K
REPL icon
8
Replimune Group
REPL
$941M
$19.8M 6.49%
+1,229,656
New +$21.6M
OPTN
9
DELISTED
OptiNose
OPTN
$18.1M 5.94%
97,236
+35,333
+57% +$10.1M
ASND icon
10
Ascendis Pharma A/S
ASND
$16B
$17.4M 5.7%
245,424
-25,000
-9% -$1.72M
ALDR
11
DELISTED
Alder Biopharmaceuticals
ALDR
$16.7M 5.46%
1,000,919
-130,000
-11% -$2.35M
OMER icon
12
Omeros
OMER
$857M
$8.69M 2.85%
+356,000
New +$7.94M
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$7.69M 2.52%
529,551
– –
EIDX
14
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$5.24M 1.72%
525,000
+279,918
+114% +$4.6M
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.06B
$5.09M 1.67%
+385,714
New +$4.47M
RCUS icon
16
Arcus Biosciences
RCUS
$3.55B
$4.11M 1.35%
295,000
– –
GRTS
17
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.49M 0.82%
+175,000
New +$2.49M
KNSA icon
18
Kiniksa Pharmaceuticals
KNSA
$5.8B
$2.41M 0.79%
94,477
– –
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$8.84B
$1.42M 0.47%
+49,600
New +$1.47M
QURE icon
20
uniQure
QURE
$3.03B
$388K 0.13%
10,650
– –
VRNA
21
DELISTED
Verona Pharma
VRNA
$104K 0.03%
+8,302
New +$107K
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-75,000
Closed -$2.24M
ALDR
23
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-350,000
Closed -$5.53M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q3 2018 Portfolio in Review

As of Q3 2018, Foresite Capital Management IV held 23 positions worth $305M, up 4% from $293M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management IV deployed $37.1M of net new capital in Q3 2018, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was Replimune Group: 1,229,656 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $3.21M trimmed.

  • Foresite Capital Management IV's largest Q3 2018 buy was Replimune Group: 1,229,656 shares worth $19.8M.
  • Foresite Capital Management IV added most to OptiNose in Q3 2018, an estimated $10.1M increase.
  • Foresite Capital Management IV's biggest Q3 2018 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $3.21M.
  • Foresite Capital Management IV fully exited Tricida, Inc. Common Stock in Q3 2018, selling an estimated $2.24M.
  • Foresite Capital Management IV's ten largest holdings make up 82% of its $305M portfolio in Q3 2018.
  • Foresite Capital Management IV opened 6 new positions and closed 2 in Q3 2018.
  • Foresite Capital Management IV's portfolio value rose 4% quarter-over-quarter to $305M.

Based on Foresite Capital Management IV's 13F filing for Q3 2018, filed 13 Nov 2018.